This post is from a suggested group
Understanding Biosimilars: The Scientific Development and Regulatory Pathway for High-Similarity Biological Therapeutic
A **biosimilar** is a biological therapeutic product that is approved based on its demonstration of **high similarity** to an already approved original biological medicine, known as the **reference product**, with no clinically meaningful differences in terms of quality, safety, or efficacy. Unlike chemically synthesized small-molecule generics that are identical copies of their reference drug, biosimilars are complex proteins derived from living systems (like cells or microorganisms), meaning they can never be exact duplicates due to inherent biological variability in the manufacturing process. The regulatory pathway for biosimilars is therefore focused not on absolute identity, but on a rigorous, stepwise comparison to establish comparable performance and patient outcomes.
The development of a biosimilar involves a comprehensive and systematic **comparability exercise** that begins with intensive structural and functional analysis. This analytical stage is the most crucial, involving advanced techniques (such as mass spectrometry and various chromatography methods) to compare the physical-chemical structure,…